B-32. Immunophacology III. (antibodies and fusion proteins). Flashcards
Polyclonal antibody therapies
- ) Intravenous Immunoglobulin (IVIG)
- ) Anti-Rho (D)
- ) Polyclonal Antibodies
- ) Hyperimmune globulins
Intravenous Immunoglobulin (IVIG) MOA
- )Neutralizes superantigens and autoantibodies
- ) Blocks macrophages FcRs
- ) Inhibits complement/immune complex-mediated tissue destruction (isolated from blood of healthy donors)
Indication of Intravenous Immunoglobulin
- ) Immune Thrombocytopenic Purpura
- Platelet surface antigen autoantibodies (anti-GP-IIb/IIIa, etc.) - ) Kawasaki disease and other vasculitis
- ) Guillain-Barre syndrome
- Muscle weakness beginning distally (C. jejuni and CMV-related) - ) Polymyositis
- unknown auto-antigen - )SLE
- ) Immunoglobulin deficit
- as in X-linked agammaglobulinemia etc.
Intravenous Immunoglobulin side effects
allergy
Indication for Anti-Rho
Given to Rh- mothers after delivery of Rh+ baby to suppress mother’s antibody production
Polyclonal Antibodies includes
Anti-lymphocyte and thymocyte globulins
Polyclonal antibodies MOA
Polyclonal antibodies from rabbit/horse immunized by human lypho-/thyomocytes that kill/block human lymphocytes
Indication for polyclonal antibodies
Transplants prevent acute rejection and used wen rejection of organ is likely.
Also a pretreatment of BM rafts with anti-lymphocyte globulins reduces incidence of GVHD
Side effects of polyclonal antibodies
- ) Dyspnea
- ) Serum sickness
- ) Fever and GI issues
What are hyperimmune globulins like? How are they different? What are they used for?
Hyperimmune globulins are similar to IVIG but isolated from donors with high titers of Ab specific to certain antigens.
Used for passive immunization of viral infections (CMV, VZV, HBV, rabies) and toxicological issues (dioxin, snake venom, etc.)
-momab means?
100% mouse
-ximab means?
chimeric; 75% human
-zumab means?
95% human
-umab means?
100% human
Anti-T cell mAbs names
- ) Muromonab-CD3
2. ) Basiliximab (Daclizumab, a humanized version)
Muromonab-CD3
MOA?
Indication?
Side effect?
Muromonab-CD3 is the first mAb drug; against CD3 (a TCR coreceptor) causing rapid reduction of T cell count.
Indication is kidney transplant, against acute rejection
Side effect is cytokine release syndrome, flu-like, sometime shock
Basiliximab MOA? Indication? Side effecs? What is Daclizumab?
MOA: Antibody against IL-2 receptor (specific CD-25, the alpha chain of IL-2R) inhibiting T-cell activation
Indication: transplants against acute rejection (less effective than anti-lymphocyte and thymocyte globulins)
Side effects: GI symptoms
Daclizumab, a humanized version, was withdrawn due to enecephalitis risk
Rituximab and Ocrelizumab MOA
Binds CD20 B cell antigen (malignant and normal B cells, but not plasma cells). A single treatment reduces B cell count for more than a month via complement and cell mediated B cell destruction.
Indications of Rituximab and Ocrelizumab
1.) B-cell lymphomas- of lower malignancy
2.) CLL
3.) Rheumatoid arthritis (2 doses in 2 weeks; again after 6 months break)
4.)Vasculitis
Off-label: treatment resistant AI diseases
5.) MS- ocrelizumab for progressive or relapsing-remitting types
Rituximab and Ocrelizumab side effects
- ) Infusion reactions- avoidable with steroid, paracetamol+ anti-HA prophylaxis
- ) Infections (and increased risk of lymphoma if given with TNF-alpha antagonist)
Other anti-CD20 mAbs
- ) Obinutuzumab (CLL, follicular lymphoma)
- ) Ofatumumab (CLL, FL, diffuse large B-cell lymphoma, RA, MS)
- ) Y90-Ibritumomab-tiuxetan
- ) Veltuzumab (NHL, non-Hodgkin lymphoma)
Alemtuzumab MOA
- Anti-CD52 mAb.
- CD52 is a glycoprotein on B-, T-, NK cells and macrophages
- Possible function as anti-adhesion molecule increased cellular movement.
Alemtuzumab indication
Used for MS, no longer used for B-cell CLL (withdrawn)
Side effect of Alemtuzumab
myelosuppresion
Anti-TNF alpha drugs
- ) Etanercept
- ) Infliximab
- ) Adalimumab
- ) Golimumab
- ) Certolizumab pegol
Etanercept is a? Binds? Given how and how often?
- A fusion protein of 2 TNF alpha receptor and IgG Fc portions
- binds free TNF alpha
- given s.c. 1-2x/week
Infliximab is a? Given how and how often?
- Chimeric mAB
- given i.v. 1-2x/month
Adalimumab is a? Given how and how often?
- human mAb
- given s.c. 1-2x/week
Golimumab is a? Given how and how often?
- human mAb
- given s.c. 1x/month
Certolizumab pegol is a? Given how and how often?
- Humanized Ab Fab fragment bound to PEG
- given s.c. 1-2x/month
Indication of infliximab and adalimumab
- ) RA
- ) Ankylosing Spondylitis
- ) Psoriasis
- ) IBD
- ) Juvenile idiopathic arthritis
(In RA, usually combined with MTX)
Certolizumab indication
Only for RA; milder effect due to no complement activation
In RA, usually combined with MTX
Etanercept indication
1.) RA
2.) Ankylosing Spondylitis
3.) Psoriasis
4.) Juvenile idiopathic arthritis
NOT IBD because it doesn’t neutralize bound TNF; may worsen symptoms
(In RA, usually combined with MTX)
Side effects of Anti-TNF alpha drugs
- ) Infections- TB, opportunistic, laten viral hepatitis reactivation
- ) Injection/infusion reactions
- ) Allergy
- ) Formation of neutralizing Abs against mAbs is possible, especially with infliximab
Drugs affecting IL-17 function
- ) Secukinumab
- ) Ixekizumab
- ) Brodalumab
Secukinumab and Ixekizumab MOA
Anti IL-17 mAb that block pro inflammatory IL-17 prodecued by Th17 cells.
Typically IL-17R activation leads to chemokine production and neutrophil and monocyte migration to inflammatory sites
Indication of Secukinumab
- ) Plaque psoriasis
2. ) Psoriatic arthristis
Indications of Ixekizumab
Ankylosing spondylitis
Side effects of Secukinumab and Ixekizumab
Respiratory infections and allergy (rhinitis)
Brodalumab MOA
Anti-IL 17 receptor mAb which has similar effects to secukinumab and ixekizumab
Indications Brodalumab
plaque psoriasis
Side effects of Brodalumab
HA, arthralgia, fatigue, diarrhea, and stomach ache
Drugs affecting IL-1 function (3)
- ) Anakinra
2. ) Canakinumab and Rilonacept
MOA of Anakinra
IL-1 receptor antagonist; long acting analog of the endogenou IL-1 receptor antagonist peptide
Indication of Anakinra
- ) RA (less effective than TNF blockers)
- ) Cryopyrin-associated periodic syndromes (cryopyrin mutation) where cold exposure causes increased IL-1B leading to fever/rash/arthralgia
Side effects of Anakinra
- ) Infections- TB, opportunistic, laten viral hepatitis reactivation
- ) Injection/infusion reactions
- ) Allergy
- ) Formation of neutralizing Abs against mAbs is possible
Canakinumab and rilonacept MOA
Canakinumab is an anti-IL1B mAb (reilonacept is a dimeric fusion protein of the EC ligand-binding part of the IL1R1 and the Fc portion of the IgG)
Integrin inhibitors (2)
Natalizumab and Vedolizumab
MOA of Natalizumab and Vedolizumab
Anti-alpha4 integrin mAb that inhibits docking and extravation of T cells
- ) What is alpha4beta1-VCAM-1 interaction necessary for?
2. ) What is alpha4beta7-MadCAM-1 interactions necessary for?
- ) CNS extravasation (MS indication)
2. ) GI tract extravasation (Crohn’s indication)
Indication for Natalizumab and Vedolizumab
multiple sclerosis and Crohn’s disease (Vedolizumab only acts on GI)
Side effects of Natalizumab and Vedolizumab
- ) Fever, nausea, infection
- ) Polyomavirus JC activation
- Can lead to progressive multifocal leukoencephalopathy (Not in the case of Vedolizumab)
Other mAbs drug names (9)
- ) Tocilizumab
- ) Sarilumab
- ) Belimumab
- ) Ustekinumab
- ) Guselkumab
- ) Reslizumab
- ) Abatacept
- ) Omalizumab
- ) Eculizumab
Tocilizumab and Sarilumab MOA
Blocks IL-6 receptor; IL-6 stimulates hepatic acute phase protein synthesis and fever
Tocilizumab Indication and kinetics
Tocilizumab is used for RA and Juvenile idiopathic arthritis
Given IV monthly
Sarilumab Indication and kinetics
Sarilumab used only for RA
Given IV/SC 2x/month
Tocilizumab and Sarilumab side effects
Similar to TNF-alpha inhibition
-Neutropenia and increase lipid levels
Belimumab MOA
mAb against B-lymphocyte-stimulator-protein (BLyS, BAFF) → inhibits auto-reactive B-cell survival + plasmacytic differentiation; normalizes low complement in SLE
Belimumab Indication
SLE
Belimumab Side effects
- ) Fever
- ) Migraine
- ) Arthralgia
- ) Leukocytopenia
Ustekinumab MOA
Ustekinumab binds common p40 subunit of both IL-12 (Th1 formation) + IL-23 (Th17 formation)
Ustekinumab indication
- ) plaque psoriasis
- ) psoriatic arthritis
- ) Crohn’s
Guselkumab MOA and indication
Only anti-IL-23 effects; for plaque psoriasis
Reslizumab MOA
anti-IL-5 mAb → ↓ eosinophil activation (also ↓ B-cell growth and Ig production)
Reslizumab Indication
bronchial asthma - severe eosinophilic forms
Reslizumab side effects
- ) CK elevation
2. ) allergy
Abatacept MOA
Abatacept is a fusion protein of CTLA-4 and Fc portion of IgG → binds to CD80/86 on APCs → blocks binding of CD28 on lymphocytes to CD80/86 → ↓ lymphocyte activation
(CD28-CD80/86 binding is normally a “co-stimulatory” signal which occurs along with the MHC-TCR interactions btwn APCs and lymphocytes)
Abatacept Indication
○ Rheumatoid arthritis
○ JIA - with uveitis
○ Psoriatic arthritis
Abatacept Side effects
○ HA, infections
○ Neutralizing antibodies - may form against the fusion protein + inhibit it
Omalizumab MOA
anti-IgE mAb, against Fc portion of IgE → ↓ circulating IgE ≤ 90%
Indications for Omalizumab
○ Bronchial asthma - severe cases
○ Chronic urticaria
Side effects of Omalizumab
allergy and local reactions
Eculizumab MOA and indication
Eculizumab is an anti-C5 mAb → ↓ complement factor 5
Used for paroxysmal nocturnal Hemoglobinuria and HUS; orphan drug